Rashid 2007.

Methods	A patient report of intensified somatic hallucinations during dose increase of methylphenidate treatment at the hospital
Participants	Diagnosis of ADHD: DSM‐IV (subtype: unknown) Age: 10 years old IQ: > 70 Sex: male Ethnicity: unknown Country: USA Comorbidity: chronic pattern of somatisation Comedication: unknown Methylphenidate‐naïve: no. OROS methylphenidate, 36 mg/day, ≥ 2 years Sociodemographics: history of several foster placements, now adopted
Interventions	Methylphenidate dose: regular‐release methylphenidate, 10 mg, twice daily, then titrated to regular‐release methylphenidate, 15 mg, twice daily, 2 days Treatment compliance: not stated
Outcomes	Serious adverse events: Hallucinations Regular‐release methylphenidate, 10 mg, twice daily Regular‐release methylphenidate, 15 mg, twice daily, 2 days: somatic hallucinations Discontinuation of methylphenidate: complete resolution of the psychotic phenomena within 2 days Follow‐up 1 year later: no unexplained somatic complaints
Notes	Funding/vested interest: no financial relationships to disclose Authors' affiliations: no affiliations to pharmaceutical companies stated Key conclusions of the study authors: here we describe a case of a 10‐year‐old boy with ADHD with a chronic pattern of somatisation, which evolved into overt somatic hallucinations with an increase in the methylphenidate dose. This pattern of somatisation was retrospectively recognised as partial somatic hallucinations Supplemental information regarding ADHD diagnostic criteria and IQ received through personal email correspondence with the authors in October 2013 (Rashid 2013 [pers comm])